Featured Research

from universities, journals, and other organizations

T-Cell Vaccine Reduces Simian Immunodeficiency Virus Levels In Semen Of Monkeys During Primary Infection

Date:
October 26, 2009
Source:
American Society for Microbiology
Summary:
A new study reports that a vaccine-induced cellular immune response reduced simian immunodeficiency virus (SIV) levels in the semen of rhesus monkeys during the period of primary infection, a discovery that may ultimately aid in the fight against HIV-1 transmission in humans.

A new study reports that a vaccine-induced cellular immune response reduced simian immunodeficiency virus (SIV) levels in the semen of rhesus monkeys during the period of primary infection, a discovery that may ultimately aid in the fight against HIV-1 transmission in humans.

The researchers from Harvard Medical School, Boston, Massachussetts; Los Alamos National Laboratory, Los Alamos, New Mexico; and the National Institute of Allergy and Infectious Diseases, Bethesda, Maryland detail their findings in the October 2009 issue of the Journal of Virology.

HIV-1 replication peaks during the period of primary infection, therefore it is estimated that 50% of sexually contracted HIV-1 cases occur when the individual transmitting the virus is newly infected. No vaccines capable of inducing antibodies that completely neutralize a variety of HIV-1 isolates are currently available, however prior studies show that vaccine-elicited, virus-specific T-lymphocyte populations can limit viral replication during primary infection in nonhuman primates.

In the study two groups of rhesus monkeys were immunized with either vaccine vectors expressing SIV Gag/Pol or control vaccine constructs following which both were challenged intravenously with a highly pathogenic SIV quasispecies. Semen samples were collected from both groups of monkeys once a week for six weeks and then bi-weekly up to 16 weeks to evaluate both the acute and set point phase of SIV viremia. Analysis of the collected semen samples showed that SIV RNA was detected by day 7 in the control group and reached a peak at day 28 postinfection, while in the Gag/Pol group SIV RNA wasn't detected until day 14, reached a peak at day 21, declined to undetectable levels by day 42 postinfection and remained that way for the duration of the study. Significantly, the peak virus RNA level in the semen of the Gag/Pol group was found to be lower than the control group and it remained substantially lower from days 28 to 80 postinfection.

"The demonstration in the present study of a direct association between vaccination and diminished seminal plasma SIV RNA levels suggests that vaccination may be an effective measure for reducing HIV-1 transmission," say the researchers.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. J.B. Whitney, C. Luedemann, P. Hraber, S.S. Rao, J.R. Mascola, G.J. Nabel, N.L. Letvin. T-Cell Vaccination Reduces Simian Immunodeficiency Virus Levels in Semen. Journal of Virology, 2009; 83 (20): 10840 DOI: 10.1128/JVI.01202-09

Cite This Page:

American Society for Microbiology. "T-Cell Vaccine Reduces Simian Immunodeficiency Virus Levels In Semen Of Monkeys During Primary Infection." ScienceDaily. ScienceDaily, 26 October 2009. <www.sciencedaily.com/releases/2009/10/091025200344.htm>.
American Society for Microbiology. (2009, October 26). T-Cell Vaccine Reduces Simian Immunodeficiency Virus Levels In Semen Of Monkeys During Primary Infection. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/10/091025200344.htm
American Society for Microbiology. "T-Cell Vaccine Reduces Simian Immunodeficiency Virus Levels In Semen Of Monkeys During Primary Infection." ScienceDaily. www.sciencedaily.com/releases/2009/10/091025200344.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins